Therapeutics News

NEW ORLEANS –The new Tyrvaya nasal spray helps the body stimulate natural tears and “work like it should,” Josh Johnston, OD, said here at SECO.

Johnson & Johnson Vision Care announced that the FDA has approved its Acuvue Theravision with Ketotifen daily disposable contact lenses.

As medical marijuana becomes increasingly legal in the U.S., eye care providers are fielding more inquiries and making decisions about its use in the treatment of glaucoma, according to a study published in the Journal of Glaucoma.

BOSTON — Results from the ARMOR study indicate that about 70% of Staphylococcus organisms in the eye are resistant to commonly used antibiotics.

BOSTON – The pH of the recently approved Vuity from Allergan, an Abbvie company, improves the drug’s availability and translates to faster pupil size reduction, according to a presentation here at the American Academy of Optometry annual meeting.

BOSTON – Orasis Pharmaceuticals anticipates finishing its phase 3 program involving CSF-1 ophthalmic solution for treating presbyopia this year, President and COO Paul Smith said here at the American Academy of Optometry meeting.

BOSTON – Vuity improves near vision without sacrificing distance vision in patients after LASIK, according to study results presented here at the American Academy of Optometry annual meeting.

BOSTON – Vuity, the first eye drop approved for treating presbyopia, showed significant improvement in acuity at intermediate distance at all hours tested through a 10-hour day, according to Chris Lievens, OD, MS, FNAP, FAAO.

BOSTON – A wide range of eye drops are being developed to manage presbyopia, Clark Chang, OD, said here at the American Academy of Optometry meeting.

Self-tonometry consistently evaluated diurnal IOP fluctuations in patients with ocular hypertension or open-angle glaucoma, according to a crossover clinical treatment trial in Optometry and Vision Science.